RYE, N.Y., April 12 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that Matthew F. Heil, Ph.D., currently Senior Vice President of Drug Development, has assumed the position of Senior Vice President of Research and Development. In his new position, Dr. Heil will have direct oversight of Curemark’s research program and all of its product development activities. As Curemark continues to anticipate expansion of its clinical trials program, Dr. Heil will oversee and coordinate all activities across a variety of Curemark product programs, the company said.
“I am excited to have the opportunity to implement Curemark’s strategic vision. This is one of the most exciting and responsible companies I have ever had the pleasure of working for,” states Heil. “Curemark is extremely focused on children with conditions for whom either no treatment or inadequate treatment is available. I am proud to oversee this research.”
Curemark currently is conducting Phase III clinical trials for CM-AT, an autism treatment that will be one of the first to address the underlying physiology of autism. CM-AT is based on Dr. Fallon’s breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. The FDA recently designated CM-AT as a Fast Track drug.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
CONTACT: Michelle Manoff, Rubenstein Public Relations, +1-212-843-8051,
mmanoff@rubensteinpr.com, or Dr. Joan Fallon, Curemark LLC,
+1-914-925-3450, joan.fallon@curemark.com
